BeiGene and EUSA Receive the NMPA's Approval of Qarziba (dinutuximab beta) for High-Risk Neuroblastoma
Shots:
- The conditional approval is based on the SIOPEN trial evaluating dinutuximab beta vs dinutuximab beta with/out IL-2 in 514 patients aged ≥12 mos. with high-risk neuroblastoma who have received induction CT & partial response along with a history of R/R neuroblastoma with/out the residual disease. The trial was conducted by SIOPEN in collaboration with Apeiron & EUSA
- The results also demonstrated the 5yrs. EFS rate (57% vs 42%) and OS rate (64% vs 50%). The safety of the therapy was also evaluated
- Qarziba is a mAb targeting carbohydrate moiety of disialoganglioside 2 (GD2) & has received the EC’s approval for the same indication in 2017
| Ref: BeiGene | Image: SybBioBeta
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com